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Characterization of five novel anti-mrsa compounds identified using a wholeanimal caenorhabditis elegans/galleria mellonella sequential-screening approach
Abstract
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. There is a significant need to combat the
growing challenge of antibacterial drug resistance. We have previously developed a whole-animal dualscreening platform that first used the nematode Caenorhabditis elegans, to identify low-toxicity
antibacterial hits in a high-throughput format. The hits were then evaluated in the wax moth caterpillar
Galleria mellonella infection model to confirm efficacy and low toxicity at a whole animal level. This multihost approach is a powerful tool for revealing compounds that show antibacterial effects and relatively
low toxicity at the whole organism level. This paper reports the use of the multi-host approach to identify
and validate five new anti-staphylococcal compounds: (1) 4,4′,4”-(4-propyl-[1H]pyrazole-1,3,5-triyl)trisphenol(PPT), (2) (1S,2S)-2-[2-[[3-(1Hbenzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl
cyclopropanecarboxylate dihydrochloride(NNC), (3) 4,5,6,7-tetrabromobe nzotriazole (TBB), (4)
3-[2-[2-chloro-4-[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy] phenyl]ethenyl] benzoic
acid(GW4064), and (5) N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-[(4-iodo-2-methylphenyl)amino]
benzamide(PD198306). The compounds reduced the severity of methicillin-resistant Staphylococcus
aureus (MRSA, strain MW2) infections in both C. elegans and G. mellonella and showed minimal inhibitory
concentrations (MICs) in the range of 2–8 µg/mL. Compounds NNC, PPT, and TBB permeabilized MRSAMW2 cells to SYTOX green, suggesting that they target bacterial membranes. Compound TBB showed
synergistic activity with doxycycline and oxacillin against MRSA-MW2, and compounds PPT, NNC,
GW4064, and PD198306 synergized with doxycycline, polymyxin-B, gentamicin, and erythromycin,
respectively. The study demonstrates the utility of the multi-host approach with follow-up hit
characterization for prioritizing anti-MRSA compounds for further evaluation.
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Abstract: There is a significant need to combat the growing challenge of antibacterial drug resistance.
We have previously developed a whole-animal dual-screening platform that first used the nematode
Caenorhabditis elegans, to identify low-toxicity antibacterial hits in a high-throughput format. The hits
were then evaluated in the wax moth caterpillar Galleria mellonella infection model to confirm
efficacy and low toxicity at a whole animal level. This multi-host approach is a powerful tool
for revealing compounds that show antibacterial effects and relatively low toxicity at the whole
organism level. This paper reports the use of the multi-host approach to identify and validate five
new anti-staphylococcal compounds: (1) 4,40 ,4”-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol(PPT),
(2) (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1(1-methylethyl)-2-naphthalenyl cyclopropanecarboxylate dihydrochloride(NNC), (3) 4,5,6,7-tetrabromobe
nzotriazole (TBB), (4) 3-[2-[2-chloro-4-[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]
phenyl]ethenyl] benzoic acid(GW4064), and (5) N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-[(4-iodo-2methylphenyl)amino] benzamide(PD198306). The compounds reduced the severity of methicillin-resistant
Staphylococcus aureus (MRSA, strain MW2) infections in both C. elegans and G. mellonella and showed
minimal inhibitory concentrations (MICs) in the range of 2–8 µg/mL. Compounds NNC, PPT,
and TBB permeabilized MRSA-MW2 cells to SYTOX green, suggesting that they target bacterial
membranes. Compound TBB showed synergistic activity with doxycycline and oxacillin against
MRSA-MW2, and compounds PPT, NNC, GW4064, and PD198306 synergized with doxycycline,
polymyxin-B, gentamicin, and erythromycin, respectively. The study demonstrates the utility of the
multi-host approach with follow-up hit characterization for prioritizing anti-MRSA compounds for
further evaluation.
Keywords: antibiotic; high-throughput screening (HTS), MRSA; MIC; Caenorhabditis elegans; Galleria
mellonella
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Table 1. List of compound names and reported bioactivities.
Compounds

Chemical Name

Reported Bioactivity

PPT

4,40 ,4”-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol

Prevents ovariectomy-induced
weight gain and loss of bone mineral
density, and induces gene expression
in the hypothalamus following
systemic administration in vivo [10].

NNC

(1S,2S)-2-[2-[[3-(1H-Benzimidazol-2yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4tetrahydro-1-(1-methylethyl)-2-naphthalenyl
cyclopropanecarboxylate dihydrochloride

Highly selective T-type calcium
channel blocker. Displays IC50
values of 6.8 and >100 µM for
inhibition of Cav 3.1 T-type channels
and HVA currents respectively in
INS-1 cells [11].

TBB

4,5,6,7-Tetrabromobenzotriazole

Cell-permeable, selective inhibitor
of casein kinase-2.Exhibits modest
discrimination between CK2
subunits [12].

GW4064

3-[2-[2-Chloro-4-[[3-(2,6-dichlorophenyl)-5-(1methylethyl)-4isoxazolyl]methoxy]phenyl]ethenyl]benzoic acid

Selective, non-steroidal farnesoid X
receptor (FXR) agonist Shown to
suppress autophagy in
nutrient-deprived mouse
hepatocytes [13].

N-(Cyclopropylmethoxy)-3,4,5-trifluoro-2-[(4-iodo-2methylphenyl)amino]-benzamide

Potent inhibitor of MEK1/2.Highly
selective for MEK.Antihyperalgesic;
blocks static allodynia in the
streptozocin model of neuropathic
pain [14].

PD198306

Table 2. Z-scores of C. elegans screening hits.
Compound

Z-Score

PPT
NNC
TBB
GW4064
PD198306

5.54
5.83
3.16
3.28
3.43

2.2. Galleria Mellonella Assays
The five hits were next tested in the G. mellonella–MRSA model to validate their activity in a second
whole-animal infection assay. Maximum tolerated doses (MTDs) were obtained by challenging
uninfected larvae with increasing doses of the compounds (10, 20, and 30 mg/kg). All five compounds
exhibited MTDs of 10 mg/kg (data not shown) and this concentration was used in the infection model.
Larvae were infected with MRSA MW2 (5 × 105 CFU) in the left rear proleg, and after two hours,
the compounds were introduced separately at 10 mg/kg into the right rear proleg and larvae survival
was monitored for 120 h. All compounds prolonged survival relative to untreated controls (Figure 2),
although none were as effective as vancomycin at 10 mg/kg. Untreated larvae showed a median
post-infection survival of only 1 day, while GW4064, NNC, PD198306, and PPT each extended median
survival to 2 days. TBB treatment extended median survival to 3 days.
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2.3. Antibacterial Susceptibility
2.3. Antibacterial Susceptibility
Antibacterial activity of the five compounds was evaluated against MRSA-MW2 (Table 3) and four
Antibacterial activity of the five compounds was evaluated against MRSA-MW2 (Table 3) and
additional clinical S. aureus isolates (Table 4). All of the compounds were found to potently inhibit the
four additional clinical S. aureus isolates (Table 4). All of the compounds were found to potently
growth of MW2 and the isolates, with each showing MICs in the range of 2–8 µg/mL. By comparison,
inhibit the growth of MW2 and the isolates, with each showing MICs in the range of 2–8 µg/mL. By
the MIC of vancomycin was 1 µg/mL against MW2 and 2 µg/mL against other isolates. The minimum
comparison, the MIC of vancomycin was 1 µg/mL against MW2 and 2 µg/mL against other isolates.
bactericidal concentration (MBC) of PPT against MW2 was 32 µg/mL, and for NNC, TBB, GW4064, and
The minimum bactericidal concentration (MBC) of PPT against MW2 was 32 µg/mL, and for NNC,
PD198306 it was >64 µg/mL. When tested against ESKAPE pathogens (Table 4), good activity (MIC,
TBB, GW4064, and PD198306 it was >64 µg/mL. When tested against ESKAPE pathogens (Table 4),
2–8 µg/mL) was seen against the Gram-positive bacterium Enterococcus faecium; however, poor activity
good activity (MIC, 2–8 µg/mL) was seen against the Gram-positive bacterium Enterococcus faecium;
was observed against Gram-negative pathogens except with PD198306, which showed modest activity
however, poor activity was observed against Gram-negative pathogens except with PD198306, which
(MIC 32 µg/mL) against Acinetobacter baumanii.
showed modest activity (MIC 32 µg/mL) against Acinetobacter baumanii.
Table 3. Antibacterial activity (µg/mL) of compounds against MRSA MW2.
Compounds
PPT
NNC
TBB
GW4064
PD198306
Vancomycin

MIC
8
8
6
8
2
1

4

MBC
32
>64
>64
>64
>64
8
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Table
4. Antibacterial activity of compounds against clinical S. aureus isolates and ESKAPE pathogens.
pathogens.
Clinical
S. aureus
Isolates
Clinical
S. aureus
Isolates
and and
ESKAPE
Pathogens
ESKAPE
Pathogens PPT PPT NNC
NNC
BF1
8
4
BF1
8
4
BF2
8
BF2
8
22
BF3
8
BF3
8
44
BF4
8
BF4
8
44
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8
Enterococcus
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pneumoniae >64 >64 >64
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Pseudomonas
aeruginosa
Pseudomonas
aeruginosa >64 >64 >64
>64
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4
4
2
2
4
4
2
2
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4
2
2
4
2
2
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8
2
2
8
2
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2
2
8
2
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8
2
4
8
2
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Figure
µg/mL and cell viability was monitored
Figure 3. MRSA-MW2 cells were exposed to compounds at 64 µg/mL
monitored
over
over 44 hr.
hr. DMSO
DMSO 0.64%
0.64% and
and vancomycin
vancomycin (16
(16 µg/mL)
µg/mL)were
wereincluded
includedas
ascontrols.
controls.

2.4. Membrane Permeabilization
2.4. Membrane Permeabilization
To determine whether the compounds target bacterial membranes, MRSA MW2 was treated with
To determine whether the compounds target bacterial membranes, MRSA MW2 was treated
the compounds and uptake of the membrane-impermeable DNA-binding fluorescent dye Sytox green
with the compounds and uptake of the membrane-impermeable DNA-binding fluorescent dye Sytox
was monitored over 1 h (Figure 4). Exposure of cells to the compounds at 64 µg/mL revealed that TBB,
green was monitored over 1 h (Figure 4). Exposure of cells to the compounds at 64 µg/mL revealed
PPT, and NNC caused increases in cellular fluorescence, suggesting that they damage the membrane.
that TBB, PPT, and NNC caused increases in cellular fluorescence, suggesting that they damage the
membrane. Compounds GW4064 and PD198306 showed no changes in cellular fluorescence,
suggesting that they do not elicit antibacterial action through effects on membranes.
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S.
aureus
proliferation at concentrations close to their S. aureus MICs.
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Figure 5. Human red blood cells (RBCs) (2%) were exposed to two-fold serial dilutions of compounds
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and hemolysis was measured after 1 hr. A sample treated with 1% Triton-X 100, which causes 100%
hemolysis, was used as the positive control.
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combined antibacterial activity of the two compounds is greater than the sum of the individual
compound activities, are identified by FIC index ≤ 0.5, antagonism by FIC index > 4.0, and no
interaction by 0.5 < FIC index < 4.0. Polymyxin-B showed synergistic activity with NNC and
gentamicin synergized with GW4064. Erythromycin showed synergy with PD198306. Doxycycline
and oxacillin both synergized with TBB, but only doxycycline with PPT. None of the compounds
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dilutions of compounds and the cytotoxicity was measured after 24 hr.
Table 5. Eukaryotic cell cytotoxicity of compounds (µg/mL).
Table 6. Fractional Inhibitory Concentration (FIC) Index of test compounds with selected antibiotics
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from different classes.

Compounds PPT
Polymyxin B
NNC
PPT
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TBB
NNC
0.5
GW4064
TBB
2.0
PD198306
GW4064
0.75
PD198306
1.0

2.6. Antibacterial Synergy
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0.5

8
Doxycycline
8
0.5
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0.5 < FIC index < 4.0. Polymyxin-B showed synergistic activity with NNC and gentamicin synergized
with GW4064. Erythromycin showed synergy 7with PD198306. Doxycycline and oxacillin both
synergized with TBB, but only doxycycline with PPT. None of the compounds antagonized the activity
of the antibiotics.
Table 6. Fractional Inhibitory Concentration (FIC) Index of test compounds with selected antibiotics
from different classes.
Compounds

Polymyxin B

Gentamycin

Erythromycin

Doxycycline

Oxacillin

PPT
NNC
TBB
GW4064
PD198306

2.0
0.5
2.0
0.75
1.0

1.0
0.75
1.0
0.5
0.625

0.75
1.0
0.625
1.0
0.5

0.5
0.75
0.5
2.06
2.0

1.0
2.0
0.5
1.0
0.75

3. Discussion
The aim of this study was to characterize the antibacterial properties of five synthetic compounds
with activity against MRSA. The activity of the compounds against MRSA was originally identified
using a C. elegans–MRSA whole-animal infection model. In this study, compound activities were
confirmed at the whole-animal level using the G. mellonella–MRSA model [5]. The G. mellonella infection
model is a quick and inexpensive way to confirm the efficacy of hit compounds against S. aureus
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in vivo [17], but is too cumbersome and labor intensive to implement for large scale screening of
chemical libraries. Hence, we used the G. mellonella model for follow-up validation of C. elegans high
throughput screening hits to enable prioritization of compounds for further characterization.
The five compounds chosen for study here (PPT, NNC, TBB, GW4064, and PD198306) all prolonged
the survival of both C. elegans and G. mellonella infected with MRSA. A literature survey revealed
that although the compounds had reported bioactivities, none had previously been reported to have
antibacterial activity. PPT is described as a subtype-selective ERα agonist. We found that the MIC
of PPT against MRSA-MW2 and four clinical isolates was 8 µg/mL. The compound showed potent
membrane permeabilizing properties and some hemolytic activity in human red blood cells, suggesting
it targets the bacterial membrane. Synergy was observed with PPT and the antibiotic doxycycline.
As a class, pyrazoles show a wide range of biological activities, including antimicrobial, antifungal,
antitubercular, anti-inflammatory, anticancer, antiviral, neuroprotective, and estrogen receptor (ER)
activity [10]. Some pyrazole derivatives have been shown to exhibit activity against both Gram positive
and Gram-negative bacteria and an N-phenyl-1H-pyrazole-4-carboxamide derivative increased the
survival of G. mellonella infected with S. aureus [18]. PPT is a highly hydrophobic pyrazole containing
three phenolic substituents and it is possible that these properties are responsible for the significant
toxicity observed against eukaryotic cells.
NNC is a reported calcium channel blocker [11]. The compound showed a MIC of 8 µg/mL against
MRSA MW2 and was slightly more potent against the other four isolates. As with PPT, NNC appears
to target the bacterial membrane, since it permeabilizes MRSA cells and shows hemolytic activity at
32 µg/mL. It was also found to be cytotoxic against all three eukaryotic cell lines.
TBB is a reported inhibitor of protein kinase 2 (CK2) [12]. The compound showed a MIC between
4–6 µg/mL against MRSA and the clinical isolates and while it appears to be membrane active against
MRSA-MW2, no red blood cell hemolysis was observed. The compound synergized with doxycycline
and oxacillin against MRSA, however, like PPT and NNC, it was also toxic to eukaryotic cell lines at
concentrations around its MIC.
GW4064 is a reported farnesoid X receptor (FXR) agonist [19] that suppresses cell proliferation in
several cancer lines, but not normal cells [20]. The compound showed a MIC of 4–8 µg/mL against the
MRSA strains and synergized with gentamycin. While GW4064 appears not to be membrane active
against MRSA MW2, it showed hemolytic activity at 8 µg/mL and was cytotoxic to eukaryotic cells.
PD198306 is a potent and selective non-ATP competitive inhibitor of MEK1/2 that shows
antihyperalgesic properties [14]. The compound showed the lowest MIC (2 µg/mL) against MRSA
MW2, which was similar for the four other isolates. Its activity was bacteriostatic and the compound
synergized with erythromycin. Importantly, PD198306 does not appear to be membrane active
against MRSA and shows no hemolytic activity, suggesting that its antibacterial action may be more
target-specific than the other compounds. However, PD198306 was also cytotoxic towards the three
eukaryotic cell lines at concentrations around its MIC, potentially reducing its attractiveness for
further study.
In summary, this study demonstrates the utility of the C. elegans/G. mellonella whole animal
dual-screening approach for identifying compounds of interest for study as new agents against MRSA.
The sequential use of two independent model hosts is a powerful tool for prioritizing compounds,
as it confirms that efficacious anti-microbial compounds identified by HTS in C. elegans are indeed
relatively non-toxic at a whole animal level and may warrant further study in vertebrate animals.
Although none of the five compounds exhibited a high level of toxicity at the whole animal level, all five
compounds did inhibit the proliferation of human cells at concentrations approximating the MICs for
MRSA. Despite this, the chemical scaffolds, particularly PD198306, represent good starting points for
traditional medicinal chemistry aimed at decreasing toxicity while maintaining antimicrobial activity.
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4. Materials and Methods
4.1. Hit Compounds
The five compounds: (4,40 ,4”-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol, PPT; (1S,2S)-2-[2-[[3(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2naphthalenyl cyclopropanecarboxylate dihydrochloride, NNC; 4,5,6,7-tetrabromobenzotriazole, TBB;
3-[2-[2-chloro-4-[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl] ethenyl]
benzoic acid, GW4064; and N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-[(4-iodo-2-methylphenyl)amino]
benzamide, PD198306) were purchased from Tocris Bioscience at the following levels of purity:
PPT: >99.7%, NNC: >98%, TBB: >99%, GW4064: >97%, and PD198306: 98.8%. These compounds
are members of a set of 185 hits identified previously in a C. elegans–MRSA-MW2 screen of 82,000
synthetic, low molecular weight compounds that block the ability of MRSA to kill nematodes [5,9].
Hits were identified based on Z-scores. Z-scores are calculated from the ratio of alive versus dead
worms after treatment with test compounds and represents the number of standard deviations (SD)
the test compound differs from the mean using the formula Z = (x − µ)/σ; where x is the raw sample
score, µ is the mean of the population and σ is the standard deviation of the population. Samples with
Z > 2σ are considered hits [5].
4.2. Galleria Mellonella Survival Assays
Assays were performed as described previously [21]. Briefly, sixteen randomly selected G. mellonella
larvae (Vanderhorst, Inc., St. Mary’s, OH, USA) between 300–350 mg were used for each test group.
MRSA-MW2 was grown in Tryptic Soy Broth (TSB), washed with phosphate buffered saline (PBS,
pH = 7.4), and diluted to OD600 = 0.3 before inoculation into G. mellonella larvae. A 10-µL inoculum
was injected into the last left proleg using a 10-µL Hamilton syringe. After 2 h, compounds were
administered into the last right proleg and larvae were incubated at 37 ◦ C. G.mellonella survival was
monitored for 120 h, and death was confirmed when there was no response. Killing curves and
differences in survival were analyzed by the Kaplan–Meier method using GraphPad Prism version
8 (GraphPad Software, La Jolla, CA, USA). Statistical analysis (Kruskal–Wallis test) was carried out
using the same program.
4.3. Antibacterial Susceptibility Assays
In vitro antibacterial activities were determined using the broth microdilution method [22].
Assays were performed as described in Clinical and Laboratory Standards Institute protocols in triplicate
using cation-adjusted Muller–Hinton broth (Becton Dickinson and Company, Franklin Lakes, NJ, USA)
in 96-well plates with a total assay volume of 100 µL. Two-fold serial dilutions of test compounds were
prepared over the concentration range of 1–64 µg/mL. The bacterial concentration was adjusted to
OD600 = 0.06. MW2 was incubated with the test compounds at 37 ◦ C for 18 h, OD600 was measured
and the lowest concentration of each compound that visually inhibited bacterial growth was reported
as the minimal inhibitory concentration (MIC) [23]. A 10 µL aliquot from each well in the MIC assays
was plated onto Muller–Hinton agar (Becton Dickinson and Company, Franklin Lakes, NJ, USA) and
incubated overnight at 37 ◦ C. The lowest concentration of compound for which no growth was observed
on agar plates was reported as the minimal bactericidal concentration (MBC).
4.4. Time-To-Kill Assays
Time-to-kill assays were performed as previously described [24]. Briefly, overnight cultures of
MRSA-MW2 were diluted in fresh Tryptic Soy Broth (TSB) to a density of 108 cells/mL and placed into
10 mL tubes (Becton Dickinson and Company, Franklin Lakes, NJ, USA). Test compounds dissolved
in DMSO over the concentration range 4–64 µg/mL were added and the tubes incubated at 37 ◦ C.
At periodic intervals, aliquots from each tube were serially diluted with TSB and plated onto tryptic
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soy agar (TSA) (Becton Dickinson and Company, Franklin Lakes, NJ, USA). CFUs were enumerated
after overnight incubation at 37 ◦ C. Assays were carried out in triplicate.
4.5. Membrane Permeabilization
Sytox Green (Life Technologies, Needham, MA, USA) membrane permeabilization assays were
performed as previously described [25]. The experiments were carried out in duplicate in 96-well plates.
Cells were grown to log phase and were harvested by centrifuging at 3700× g for 5 min. The cells were
washed twice with PBS and resuspended to OD600 = 0.2, following which 5 µM Sytox green was added
to the cells and the bacteria-dye mixture were incubated in the dark for 30 mins.
Cell suspensions (50 µL) were added to 50 µL of test compounds (64 µg/mL in PBS) and
fluorescence intensity was measured (excitation 485 nm, emission 530 nm) periodically over 60 min.
Bithionol, which our laboratory previously showed permeabilizes MRSA [26], was used as a positive
control. Membrane damage caused by compounds was indicated by increases in cellular fluorescence
caused by enhanced permeability of the DNA staining, membrane-impermeable dye.
4.6. Human Red Blood Cell (RBC) Hemolysis Assays
Human erythrocytes (Rockland Immunochemicals, Limerick, PA, USA) were used to measure
hemolytic activity of the compounds, as previously described [27]. Human erythrocytes (4% in PBS,
50 µL) were added to 50 µL of test compounds serially diluted in PBS, with Triton X-100 and PBS
serving as a positive and negative controls, respectively. After incubation at 37 ◦ C for 1 hr, the plates
were centrifuged at 500× g for 5 min and 50 µL of the supernatant was transferred from each well
to a second 96-well plate and the absorbance at 540 nm was measured. Assays were carried out
in triplicate.
4.7. Cytotoxicity Assays
Mammalian cell lines HepG2 (hepatic cells), A549 (epithelial cells), and MKN-28 (gastric
cells) were used to measure the anti-proliferative properties of test compounds, as described
elsewhere [28]. Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Waltham,
MA, USA) supplemented with 10% Fetal Bovine Serum (FBS) (Gibco, Waltham, MA, USA) and
1% penicillin/streptomycin (Gibco, Waltham, MA, USA) and maintained at 37 ◦ C in 5% CO2 .
After harvesting, the cells were suspended in DMEM and 100 µL was added to the wells of 96-well
plates. The test compounds were serially diluted in serum and antibiotic free DMEM, added to the
monolayer of cells, and incubated at 37 ◦ C in 5% CO2 for 24 hr. Percentage survival was calculated by
comparison to DMSO-treated vehicle controls. Assays were carried out in triplicate.
4.8. Checkboard Assays
Antibacterial synergy for combinations of the compounds with each other and with clinical
antibiotics (doxycycline, gentamicin, polymyxin-B, oxacillin, and erythromycin) was measured using
checkerboard assays. In short, Cultures of MRSA-MW2 were adjusted to OD600 = 0.06 and one
compound was arrayed horizontally and other vertically in 96 well plates. The assays were carried out
in triplicate, exactly as described for the antibacterial susceptibility assays. The inhibitory effects of
compound combinations were evaluated using the Fractional Inhibitory Concentration (FIC) index,
derived from the formula:
FIC index = FICA + FICB = [A]/MICA + [B]/MICB
MIC of substance A tested in combination /MIC of substance A tested alone + MIC of substance
B tested in combination/MIC of substance B tested alone. Synergy is indicated when FIC ≤ 0.5,
indifference when 0.5 ≤ FIC ≤ 4, and antagonism when FIC > 4. Experiments were performed in
duplicate and report the average FIC index [29].
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